• Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million
  • The company will issue up to 2,000 debenture units at $1,000 per unit
  • Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares
  • The proceeds from the offering will be used for general working capital purposes
  • Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing
  • Skylight Health Group Inc. (SLHG) opened trading at $0.7369

Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million.

The company will issue up to 2,000 debenture units at $1,000 per unit.

Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares, and shall have a maturity date of February 15, 2025.

Each debenture shall be convertible into 1,111 common shares at C$0.90. Each debenture holder shall also receive 1,111 share purchase warrants. Each warrant entitles the holder to purchase one common share for a period 24 months.

The proceeds from the offering will be used for general working capital purposes.

The offering is expected to close on or about August 15, 2022.

Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing.

Skylight Health Group Inc. (SLHG) opened trading at $0.7369.


More From The Market Online

Dream Water Kids Sleep Gummies set for US summer debut

Delivra Health (TSXV:DHB) will launch a new line of kids sleep gummies under its Dream Water brand across the US market this June.

Buzz on the Bullboards: Oil shock, biotech breakthroughs and new tech

Global equities lurched from rally to rout since the U.S.–Israel strikes on Iran ignited a regional war and shutdown of the Strait of Hormuz.

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.